COVID-19: SCAI and CAIC launch registry to provide vital data for managing patients


The Society for Cardiovascular Angiography and Interventions (SCAI) and Canadian Association of Interventional Cardiology (CAIC) have formed the North American COVID-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI). The study will be chaired by Tim Henry (SCAI) and Payam Dehghani (CAIC).

According to a press release, any COVID-19 positive patients or persons under investigation (PUI) with ST-segment elevation or new-onset left bundle branch block with a clinical correlate of myocardial ischaemia (chest pain, dyspnoea, cardiac arrest, haemodynamic instability) will be in enrolled.

The data will be compared to an age and gender-matched control population from the existing Midwest STEMI Consortium, which is a large (>15,000), prospective multicentre registry of consecutive STEMI patients. The NACMI registry has pending central IRB approval and will have an ECG and angiographic core lab.

Interested sites can designate a local principal investigator and contact either SCAI principal investigator Tim Henry ([email protected]), CAIC principal investigator Payam Dehghani ([email protected]) or the data coordinating centre ([email protected] or ross[email protected]) to obtain participating site information.

The press release reports that SCAI and CAIC believe that this registry “has the potential to provide critically important time-sensitive data to inform the management and treatment guidelines applicable to COVID-19 patients”.


Please enter your comment!
Please enter your name here